An illustration depicting pulmonary hypertension. Credit: BruceBlaus.

US-based PhaseBio Pharmaceuticals has started dosing pulmonary arterial hypertension (PAH) patients in an open-label study to assess its investigational candidate PB1046.

Developed as a once-weekly formulation, PB1046 is an agonist of vasoactive intestinal peptide (VIP) receptor designed to target VPAC receptors in the pulmonary, cardiovascular and immune systems.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

PB1046 contains a VIP analogue fused with the firm’s elastin-like polypeptide (ELP) biopolymer.

The open-label, single cohort, exploratory study will evaluate the tolerability, safety and hemodynamic response of individually dose-titrated PB1046 administered to adult PAH subjects having a permanently implanted hemodynamic monitor, CardioMEMS HF System.

Additionally, the study will monitor pharmacokinetics, exercise capacity via the six-minute walk distance test, along with exploratory biomarkers.

“VIP-based therapies such as PB1046 have the potential to provide benefit to patients who currently lack adequate treatment options.”

PhaseBio chief medical officer John Lee said:  “Previous studies have demonstrated that reduced VIP levels may be a critical factor in PAH disease development and progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Consequently, VIP-based therapies such as PB1046 have the potential to provide benefit to patients who currently lack adequate treatment options.”

Data obtained from the open-label study is expected to support a placebo-controlled Phase II trial scheduled to commence early next year.

In a previous Phase I trial, PB1046 is reported to have demonstrated favourable tolerability and a prolonged dose-dependent effect on blood pressure of essential hypertension patients.

The drug candidate had obtained orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of PAH and cardiomyopathy caused due to dystrophinopathies.

Currently, PB1046 is being further studied in a Phase IIa ascending dose trial for treating heart failure patients.